170 related articles for article (PubMed ID: 22849758)
1. Progesterone for hot flush and night sweat treatment--effectiveness for severe vasomotor symptoms and lack of withdrawal rebound.
Prior JC; Hitchcock CL
Gynecol Endocrinol; 2012 Oct; 28 Suppl 2():7-11. PubMed ID: 22849758
[TBL] [Abstract][Full Text] [Related]
2. Oral micronized progesterone for vasomotor symptoms--a placebo-controlled randomized trial in healthy postmenopausal women.
Hitchcock CL; Prior JC
Menopause; 2012 Aug; 19(8):886-93. PubMed ID: 22453200
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness of sublingual and topical compounded bioidentical hormone replacement therapy in postmenopausal women: an observational cohort study.
Ruiz AD; Daniels KR
Int J Pharm Compd; 2014; 18(1):70-7. PubMed ID: 24881343
[TBL] [Abstract][Full Text] [Related]
4. Hot flushes and night sweats differ in associations with cardiovascular markers in healthy early postmenopausal women.
Hitchcock CL; Elliott TG; Norman EG; Stajic V; Teede H; Prior JC
Menopause; 2012 Nov; 19(11):1208-14. PubMed ID: 22781788
[TBL] [Abstract][Full Text] [Related]
5. Progesterone therapy increases free thyroxine levels--data from a randomized placebo-controlled 12-week hot flush trial.
Sathi P; Kalyan S; Hitchcock CL; Pudek M; Prior JC
Clin Endocrinol (Oxf); 2013 Aug; 79(2):282-7. PubMed ID: 23252963
[TBL] [Abstract][Full Text] [Related]
6. Progesterone for treatment of symptomatic menopausal women.
Prior JC
Climacteric; 2018 Aug; 21(4):358-365. PubMed ID: 29962247
[TBL] [Abstract][Full Text] [Related]
7. A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women.
Blümel JE; Chedraui P; Baron G; Belzares E; Bencosme A; Calle A; Danckers L; Espinoza MT; Flores D; Gomez G; Hernandez-Bueno JA; Izaguirre H; Leon-Leon P; Lima S; Mezones-Holguin E; Monterrosa A; Mostajo D; Navarro D; Ojeda E; Onatra W; Royer M; Soto E; Tserotas K; Vallejo S;
Menopause; 2011 Jul; 18(7):778-85. PubMed ID: 21407137
[TBL] [Abstract][Full Text] [Related]
8. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
[TBL] [Abstract][Full Text] [Related]
9. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
[TBL] [Abstract][Full Text] [Related]
10. Impact of the severity of vasomotor symptoms on health status, resource use, and productivity.
Whiteley J; Wagner JS; Bushmakin A; Kopenhafer L; Dibonaventura M; Racketa J
Menopause; 2013 May; 20(5):518-24. PubMed ID: 23403500
[TBL] [Abstract][Full Text] [Related]
11. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
Simon JA;
Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
[TBL] [Abstract][Full Text] [Related]
12. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L
Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
[TBL] [Abstract][Full Text] [Related]
13. MF-101, an estrogen receptor beta agonist for the treatment of vasomotor symptoms in peri- and postmenopausal women.
Stovall DW; Pinkerton JV
Curr Opin Investig Drugs; 2009 Apr; 10(4):365-71. PubMed ID: 19337958
[TBL] [Abstract][Full Text] [Related]
14. 17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial.
Kaunitz AM; Bitner D; Constantine GD; Bernick B; Graham S; Mirkin S
Menopause; 2020 Dec; 27(12):1382-1387. PubMed ID: 32740481
[TBL] [Abstract][Full Text] [Related]
15. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
[TBL] [Abstract][Full Text] [Related]
16. Oral micronized progesterone for perimenopausal night sweats and hot flushes a Phase III Canada-wide randomized placebo-controlled 4 month trial.
Prior JC; Cameron A; Fung M; Hitchcock CL; Janssen P; Lee T; Singer J
Sci Rep; 2023 Jun; 13(1):9082. PubMed ID: 37277418
[TBL] [Abstract][Full Text] [Related]
17. Vasomotor symptoms and cardiovascular disease risk.
Pines A
Climacteric; 2011 Oct; 14(5):535-6. PubMed ID: 21848496
[TBL] [Abstract][Full Text] [Related]
18. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States.
Williams RE; Kalilani L; DiBenedetti DB; Zhou X; Granger AL; Fehnel SE; Levine KB; Jordan J; Clark RV
Climacteric; 2008 Feb; 11(1):32-43. PubMed ID: 18202963
[TBL] [Abstract][Full Text] [Related]
19. Bioidentical progesterone cream for menopause-related vasomotor symptoms: is it effective?
Whelan AM; Jurgens TM; Trinacty M
Ann Pharmacother; 2013 Jan; 47(1):112-6. PubMed ID: 23249728
[TBL] [Abstract][Full Text] [Related]
20. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.
Bouchard P; Panay N; de Villiers TJ; Vincendon P; Bao W; Cheng RJ; Constantine G
Climacteric; 2012 Feb; 15(1):12-20. PubMed ID: 22066790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
